Dr Ahilya Singh has worked on developing and running methods for the detection, quantification, purification and analysis of biologically active compounds from natural sources over the past 10 years. This has given her extensive experience in the application of analytical chemistry techniques like liquid chromatography, mass spectrometry and nuclear magnetic resonance spectroscopy within the field of early phase drug discovery. Her PhD research focused on the isolation and characterization of target compounds from Australian rainforest plants and activity testing for use in cellular models of inflammation.
She joined the ProCan team in 2022, where she continues to apply the use of liquid chromatography- mass spectrometry in the study of the proteomics of human cancer samples. She is further developing her technical, analytical and bioinformatic skills at ProCan and enjoys working as part of a large, collaborative team.